Loading...
Market
Story
FDA Grants Accelerated Approval to EPKINLY®, First Bispecific Antibody for Relapsed/Refractory Follicular Lymphoma
Jun 26, 2024, 11:38 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Epcoritamab, marketed as EPKINLY®, for the treatment of relapsed or refractory follicular lymphoma (R/R FL). This approval marks the second for EPKINLY® and makes it the first bispecific antibody approved for both R/R FL and relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in the U.S. The drug is developed by AbbVie and Genmab, trading under the stock symbols $ABBV and $GMAB respectively. The approval has been highlighted in the #lymsm and #oncology communities.
View original story
Similar markets
None • 33%
1-3 • 33%
More than 3 • 33%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
1 additional indication • 25%
2 additional indications • 25%
3 or more additional indications • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%